Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...

The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...

Just like the brand’s logo, the brand’s name is full of meaning, too. In an Instagram video, Meghan explained, “As Ever essentially means ‘as it’s always been,’ and if you’ve ...

Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she was rebranding her lifestyle venture previously known as ...

Approval of biosimilar products can increase patient access to safe and effective treatment options. The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC. “The FDA has now approved three ...

In March 2023, Sanofi and Novo came under fire from Sen. Bernie Sanders (I-Vt), who asked the companies to follow in the footsteps of fellow diabetes leader Eli Lilly and lower the price of their ...

Most outdoor brand logos are bland as a soggy sandwich left out in the rain. But not Patagonia's. Their logo is like a breath of fresh mountain air in a world of corporate stuffiness. I remember the ...

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. A scheduled review by the study ...